Functional magnetic resonance imaging

Exploring Parkinson's Disease Statistics: Market Insight, Epidemiology ,Forecast Price and Market Access ,Commercial Strategy Analysis, Drug Development & Healthcare Consulting Services by Disease landscape Insights

Retrieved on: 
Thursday, September 14, 2023
Non-invasive ventilation, Health care, DSM-IV codes, Diverticulitis, Cerebrospinal fluid, Protein, Patient, Risk, Disease, Tremor, Genetics, Spinal cord, Gait abnormality, Genetic testing, Brain, Dopamine, Research, Approximation error, Magnetic resonance, Biomarker, Parkinson's disease, DLI, Diagnosis, Alzheimer's disease, FDA, Magnetic resonance imaging, Horizon, Safety, Exercise, Functional magnetic resonance imaging, DBS, Algorithm, Roger Hawkins (drummer), Research and development, Central nervous system, Clinical trial, Quality of life, Deep brain stimulation, Movement, MRI, L-DOPA, Scan (company), AI, Artificial intelligence, Pharmaceutical industry, Medical imaging, Medical device, Forestry, Dietary supplement

Advancements in Parkinson's Disease Diagnosis: Facilitating Patient Care

Key Points: 
  • Advancements in Parkinson's Disease Diagnosis: Facilitating Patient Care
    Parkinson's Disease can be challenging to diagnose, often leading to delayed treatment initiation.
  • However, recent advancements in diagnostic tools have empowered healthcare professionals to identify the disease more accurately and at earlier stages.
  • DiseaseLandscape Insights is at the forefront of drug insights and discovery, product launches, and clinical trial feasibility analysis in the fight against Parkinson's Disease.
  • The Parkinson's Disease Overview by healthcare consulting services provider DLI shows that it is competitive, with pharmaceutical companies vying to develop better treatments.

electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury

Retrieved on: 
Thursday, March 23, 2023
Traumatic brain injury, University of New Mexico, Center for Disease Dynamics, Economics & Policy, Disability, TBI, Functional magnetic resonance imaging, Journal of Neurotrauma, ECOR, Death, MRI, NVN, Magnetic resonance imaging, Medical imaging

The lead author is Dr. Afshin Divani of the University of New Mexico, who is the primary investigator leading the study.

Key Points: 
  • The lead author is Dr. Afshin Divani of the University of New Mexico, who is the primary investigator leading the study.
  • Traumatic brain injury (TBI) is a significant cause of death and disability worldwide.
  • MRI data suggest that the benefits may be caused by a decrease in the deformation and swelling of brain tissue after TBI.
  • We appreciate the efforts of Professor Divani and his team as well as the support of NINDS for their funding of this ongoing effort.”

Small Pharma Reports Fiscal Third Quarter 2023 Highlights

Retrieved on: 
Wednesday, January 25, 2023
SEDAR, Safety, PD, TSX Venture Exchange, Participation, University College London, MDD, Cognition, DMT, Functional magnetic resonance imaging, Pharmacokinetics, Service, MADRS, IM, Intellectual property, Magnetic resonance, Agreement, Patient, Loss, Patent, PK, Grammatical mood, GBP, Major depressive disorder, Knowledge, Selective serotonin reuptake inhibitor, Substituted tryptamine, Brain, USD, Pharmaceutical industry, Medical device

LONDON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, has today published its financial results for the three and nine months ended November 30, 2022. A full copy of the financial results can be found under the Company’s profile on SEDAR at www.sedar.com. Unless otherwise indicated, all currency references are in Canadian dollars.

Key Points: 
  • LONDON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, has today published its financial results for the three and nine months ended November 30, 2022.
  • Preparations for Phase IIb international multi-site clinical trial of SPL026 in MDD continues, with anticipated initiation in H1 2023.
  • First patient dosed in January 2023 in the Phase I study exploring intramuscular (“IM”) administration of SPL026.
  • In the third fiscal quarter we made strong progress across our clinical trials, with two new SPL026 studies now underway and patient screening initiated in our first in-human trial with SPL028.

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury

Retrieved on: 
Thursday, October 20, 2022
GLOBE, Brain, Nursing care plan, TBI, ECOR, Magnetic resonance imaging, Nerve conduction study, Traumatic brain injury, Program, NVN, Functional magnetic resonance imaging, Annual general meeting, University, MRI, NCS, Pharmaceutical industry, Medical imaging

The control group showed significant deficits in 3 common neurobehavioral assessments including rotarod, anxiety, and modified beam walking performances.

Key Points: 
  • The control group showed significant deficits in 3 common neurobehavioral assessments including rotarod, anxiety, and modified beam walking performances.
  • MRI data suggest that the benefits may be caused by a decrease in the deformation and swelling of brain tissue after TBI.
  • Traumatic brain injury is a significant cause of death and disability worldwide.
  • When placed on a patients neck over the vagus nerve, gammaCore stimulates the nerves afferent fibers, which may lead to a reduction of pain in patients.

Brain Monitoring Global Market Report 2022: Increasing Prevalence of Neurological Disorders Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 21, 2022
Neurology, Health, Medical Devices, Functional magnetic resonance imaging, Lists of diseases, Incidence, Magnetic resonance, Prevalence, Asia-Pacific, World, World Health Organization, Varian Medical Systems, MRI, Acquisition, Growth, Artificial intelligence, University of Helsinki, Robotics, WHO, EEG, University, Canon Medical Systems Corporation, Insulation monitoring device, Medical device, Medical imaging, Electroencephalography

The "Brain Monitoring Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Brain Monitoring Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in the brain monitoring market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The increasing incidence and prevalence of neurological disorders are expected to propel the growth of the brain monitoring market going forward.
  • Therefore, the rising demand for increasing incidence and prevalence of neurological disorders is driving the growth of the brain monitoring market.

New Study from StrategyR Highlights a $2 Billion Global Market for Neuromarketing Solutions by 2026

Retrieved on: 
Thursday, June 23, 2022
CAGR, MEG, COVID-19, Players, Intelligence, Functional magnetic resonance imaging, Research, Forecasting, SensoMotoric Instruments, PET, GIA, Technology, Magnetic resonance, Growth, EEG, Solution, Marketing, Internet, Positron emission tomography, SAN, Renewable energy, Pet, Electroencephalography, Others, Magnetoencephalography

SAN FRANCISCO, June 23, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Neuromarketing Solutions - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, June 23, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Neuromarketing Solutions - Global Market Trajectory & Analytics" .
  • Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more.
  • Preview Registry
    Amid the COVID-19 crisis, the global market for Neuromarketing Solutions estimated at US$1.2 Billion, is projected to reach a revised size of US$2 Billion by 2026, growing at a CAGR of 8.8% over the analysis period.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

Audeze and SMRT Image announce breakthrough headphones to improve patient comfort, and to support neuroscience research

Retrieved on: 
Monday, August 2, 2021
Neuroimaging, Magnetic resonance imaging, Branches of biology, Radiology, Neuroscience, Cognitive neuroscience, Functional magnetic resonance imaging, Headphones, Medicine

He is also the Co-Founder and Chief Scientist at SMRT Image where he is helping to solve some of the most challenging patient comfort problems with MRI.

Key Points: 
  • He is also the Co-Founder and Chief Scientist at SMRT Image where he is helping to solve some of the most challenging patient comfort problems with MRI.
  • Working with Dr. Cohen and his team at SMRT Image, Audeze helped develop new headphones that alleviate many of the acoustic issues associated with MRI testing.
  • "What we set out to do at SMRT was create a tranquil patient experience within a very hostile environment," says Tylor Garland, CEO of SMRT Image.
  • Lumica is an integrated audio-video solution offering superior patient comfort, two-way communication, and fMRI brain mapping capabilities for both clinical and research applications.

FieldLine Launches HEDscan™, a Next-Generation Device for Non-Invasive Functional Brain Imaging

Retrieved on: 
Wednesday, June 2, 2021
Branches of biology, Neuroimaging, Neuroscience, Medicine, Electrodiagnosis, Neurotechnology, Magnetic resonance imaging, Cognitive neuroscience, Functional near-infrared spectroscopy, Functional magnetic resonance imaging, Magnetoencephalography, Electroencephalography

BOULDER, Colo., June 1, 2021 /PRNewswire/ -- FieldLine Inc., a biotech company targeting advanced brain diagnostic technology, announced today the general availability of the FieldLine HEDscan system the world's first commercially available non-cryogenic, whole-head magnetoencephalography (MEG) system for functional brain imaging.

Key Points: 
  • BOULDER, Colo., June 1, 2021 /PRNewswire/ -- FieldLine Inc., a biotech company targeting advanced brain diagnostic technology, announced today the general availability of the FieldLine HEDscan system the world's first commercially available non-cryogenic, whole-head magnetoencephalography (MEG) system for functional brain imaging.
  • "HEDscan enables functional brain imaging in a broad subject population and at a price point that is accessible to most institutions.
  • Magnetoencephalography is a non-invasive brain imaging technique that works by directly detecting tiny changes in magnetic fields produced by neuronal currents.
  • Other brain imaging technologies either rely on slow and indirect measurements of the hemodynamic response (like fMRI and fNIRS)or give poor spatial information (like EEG).

Research Provides New Insight on Functional Changes That Regular Coffee Drinking has on The Brain

Retrieved on: 
Tuesday, April 20, 2021
Branches of biology, Psychoactive drugs, Neuroscience, Magnetic resonance imaging, Neuroimaging, Cerebrum, Anxiolytics, Theanine, Caffeine, Coffee, Functional magnetic resonance imaging, Striatum

These areas of the brain include the cerebellum, striatum, thalamus, parahipocampus, and the lingual and inferior occipital gyri1.\nInterestingly, the structural and connectivity differences observed among regular coffee drinkers in this research also occurred in non-coffee drinkers soon after they consumed a cup of coffee.

Key Points: 
  • These areas of the brain include the cerebellum, striatum, thalamus, parahipocampus, and the lingual and inferior occipital gyri1.\nInterestingly, the structural and connectivity differences observed among regular coffee drinkers in this research also occurred in non-coffee drinkers soon after they consumed a cup of coffee.
  • By using fMRI technology, we were able to observe the effect of coffee on the brain\xe2\x80\x99s functional connectivity and structure, and the differences between regular coffee drinkers and non-coffee drinkers, in real-time.
  • (2021) Habitual coffee drinkers display a distinct pattern of brain functional connectivity.
  • (2018) l - Theanine and caffeine improve target-specific attention to visual stimuli by decreasing mind wandering: a human functional magnetic resonance imaging study.

IXICO selected by Cyclerion for new Alzheimer's disease study

Retrieved on: 
Tuesday, March 2, 2021
Neuroimaging, Branches of biology, Magnetic resonance imaging, Neuroscience, Medicine, Radiology, Nuclear magnetic resonance, Cognitive neuroscience, Arterial spin labelling, IXICO, Resting state fMRI, Functional magnetic resonance imaging

For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging (MRI), diffusion MRI (dMRI), resting state functional MRI (rs-fMRI) and arterial spin labelling (ASL).

Key Points: 
  • For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging (MRI), diffusion MRI (dMRI), resting state functional MRI (rs-fMRI) and arterial spin labelling (ASL).
  • Alzheimer's disease (AD) is a progressive degenerative disease affecting approximately 50 million people worldwide with devastating physical, emotional and financial impact to patients and families.
  • Lammert Albers, Chief Commercial Officer of IXICO, commented: "IXICO is thrilled to be chosen by Cyclerion Therapeutics and take part in this important Alzheimer's disease trial.There are currently no means to prevent or delay onset, slow progression or meaningfully improve symptoms of this devastating disease.
  • Chris Wright, Chief Medical Officer at Cyclerion, said:"We are pleased to leverage IXICO's neuroimaging services in this new Alzheimer's disease study.